Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.77 | N/A | -19.43% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.77 | N/A | -19.43% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about current operational challenges. They highlighted their commitment to overcoming these issues but did not provide any forward guidance.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to address operational hurdles.
There was no specific outlook provided for future performance.
Disc Medicine Inc's earnings report indicates a significant miss on EPS, which contributed to a 1.48% decline in stock price. The lack of revenue data and forward guidance adds uncertainty for investors. Management's defensive tone suggests they are facing challenges that may impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025